Brisbane Clinical Trials
The Guardian Study
This is a biosimilar study to compare an already approved medication used to prevent RSV in high-risk infants and young children with this study drug.
2 nights
14 visits
Respiratory syncytial virus (RSV) is a major viral pathogen which causes serious respiratory illness in infants and children worldwide. Approximately 0.5% to 2.5% of all children infected with RSV are hospitalised with lower respiratory tract infections such as pneumonia.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!
Eligibility
Biological Sex Healthy males and females
Age 18 - 55 years old
BMI 18 - 30 kg/m²
Body Weight 50 - 95 kg
Medical History No significant medical history
Medications Not taking any medications
Smoking History Non-smokers or smokers who can abstain 7 days prior to the inpatient stay until discharged